Genome-wide association study of response to tumour necrosis factor inhibitor therapy in rheumatoid arthritis
- PMID: 30166627
- PMCID: PMC6150911
- DOI: 10.1038/s41397-018-0040-6
Genome-wide association study of response to tumour necrosis factor inhibitor therapy in rheumatoid arthritis
Abstract
Rheumatoid arthritis (RA) is characterised by chronic synovial joint inflammation. Treatment has been revolutionised by tumour necrosis factor alpha inhibitors (TNFi) but each available drug shows a significant non-response rate. We conducted a genome-wide association study of 1752 UK RA TNFi-treated patients to identify predictors of change in the Disease Activity Score 28 (DAS28) and subcomponents over 3-6 months. The rs7195994 variant at the FTO gene locus was associated with infliximab response when looking at a change in the swollen joint count (SJC28) subcomponent (p = 9.74 × 10-9). Capture Hi-C data show chromatin interactions in GM12878 cells between rs2540767, in high linkage disequilibrium with rs7195994 (R2 = 0.9) and IRX3, a neighbouring gene of FTO. IRX3 encodes a transcription factor involved in adipocyte remodelling and is regarded as the obesity gene at the FTO locus. Importantly, the rs7195994 association remained significantly associated following adjustment for BMI. In addition, using capture Hi-C data we showed interactions between TNFi-response associated variants and 16 RA susceptibility variants.
Conflict of interest statement
The authors declare that they have no conflict of interest.
Comment in
-
Unravelling the pharmacogenomics of TNF inhibition.Nat Rev Rheumatol. 2018 Dec;14(12):689-690. doi: 10.1038/s41584-018-0114-5. Nat Rev Rheumatol. 2018. PMID: 30425331 No abstract available.
Similar articles
-
Estimation of heritability of different outcomes for genetic studies of TNFi response in patients with rheumatoid arthritis.Ann Rheum Dis. 2015 Dec;74(12):2183-7. doi: 10.1136/annrheumdis-2014-205541. Epub 2014 Aug 11. Ann Rheum Dis. 2015. PMID: 25114059
-
Relationship between exposure to tumour necrosis factor inhibitor therapy and incidence and severity of myocardial infarction in patients with rheumatoid arthritis.Ann Rheum Dis. 2017 Apr;76(4):654-660. doi: 10.1136/annrheumdis-2016-209784. Epub 2017 Jan 10. Ann Rheum Dis. 2017. PMID: 28073800 Free PMC article.
-
Randomised controlled trial of tumour necrosis factor inhibitors against combination intensive therapy with conventional disease-modifying antirheumatic drugs in established rheumatoid arthritis: the TACIT trial and associated systematic reviews.Health Technol Assess. 2014 Oct;18(66):i-xxiv, 1-164. doi: 10.3310/hta18660. Health Technol Assess. 2014. PMID: 25351370 Free PMC article. Clinical Trial.
-
Optimizing biological treatment in rheumatoid arthritis with the aid of therapeutic drug monitoring.Dan Med J. 2016 Nov;63(11):B5311. Dan Med J. 2016. PMID: 27808043 Review.
-
Sarilumab for Previously-Treated Moderate or Severe Rheumatoid Arthritis: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.Pharmacoeconomics. 2018 Dec;36(12):1427-1437. doi: 10.1007/s40273-018-0677-7. Pharmacoeconomics. 2018. PMID: 29882210 Review.
Cited by
-
Genome-Wide Approach to Measure Variant-Based Heritability of Drug Outcome Phenotypes.Clin Pharmacol Ther. 2021 Sep;110(3):714-722. doi: 10.1002/cpt.2323. Epub 2021 Jul 12. Clin Pharmacol Ther. 2021. PMID: 34151428 Free PMC article.
-
Association of polymorphisms in promoter region of TNF-α -238 and -308 with clinical outcomes in patients with immune-mediated inflammatory diseases on anti-TNF therapy.Rheumatol Int. 2021 Dec;41(12):2195-2203. doi: 10.1007/s00296-021-05016-w. Epub 2021 Oct 8. Rheumatol Int. 2021. PMID: 34623480
-
Prediction of treatment response in rheumatoid arthritis patients using genome-wide SNP data.Genet Epidemiol. 2018 Dec;42(8):754-771. doi: 10.1002/gepi.22159. Epub 2018 Oct 12. Genet Epidemiol. 2018. PMID: 30311271 Free PMC article.
-
Title Current Status of the Search for Biomarkers for Optimal Therapeutic Drug Selection for Patients with Rheumatoid Arthritis.Int J Mol Sci. 2021 Sep 2;22(17):9534. doi: 10.3390/ijms22179534. Int J Mol Sci. 2021. PMID: 34502442 Free PMC article. Review.
-
Circulating Pro- and Anti-Inflammatory Metabolites and Its Potential Role in Rheumatoid Arthritis Pathogenesis.Cells. 2020 Mar 30;9(4):827. doi: 10.3390/cells9040827. Cells. 2020. PMID: 32235564 Free PMC article. Review.
References
-
- Symmons D, Turner G, Webb R, Asten P, Barrett E, Lunt M, et al. The prevalence of rheumatoid arthritis in the United Kingdom: new estimates for a new century. Rheumatology. 2002;41:793–800. - PubMed
-
- Keystone EC, Ware CF. Tumor necrosis factor and anti-tumor necrosis factor therapies. J Rheumatol Suppl. 2010;85:27–39. - PubMed
-
- Idriss HT, Naismith JH. TNF alpha and the TNF receptor superfamily: structure-function relationship(s) Microsc Res Tech. 2000;50:184–95. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical